Antazoline mesylate
Status | Commercial |
Development phase | |
Therapeutic cat. | Other |
Polymorphic form | |
CAS No. | 3131-32-6 |
Reference Product | |
Injectable Form | |
EU DMF readiness | |
CEP | |
CHINESE DMF | |
JAPANESE DMF | |
KOREAN DMF | |
CANADIAN DMF | |
CADIFA | |
US DMF readiness | |
OEB No. | |
Samples |
Drug description
Polpharma API
- Long experience in in-house commercial manufacturing
- In house production of the whole product family (Antazolines)
- No risk of nitrosoamine presence
- All intermediates produced in-house
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).